Lung cancer is the leading cause of cancer death among both men and women and accounts for about one-quarter of all cancer deaths in the United States: more than breast, prostate and colorectal cancers combined. While the treatment landscape is continuing to advance and evolve rapidly, there remains significant treatment challenges and unmet need for patients.
Lung cancer is at the forefront of AstraZeneca’s research and development focus. At the European Society for Medical Oncology World Congress, September 19-21, AstraZeneca shared lung cancer data from the Phase 3 PACIFIC, ADAURA and CASPIAN clinical trials as part of the company’s ongoing commitment to address the unmet need for treatments at every type and stage of the disease.
In this episode of MedCity Pivot podcast, we talk with Camille Hertzka, AstraZeneca’s U.S. Head of Medical Affairs Oncology, about the clinical study findings on lung cancer presented at ESMO and the rapidly changing landscape for lung cancer treatment.
